Attached files
| file | filename |
|---|---|
| 8-K - 8-K - LUMINEX CORP | lmnx-20210208.htm |
Exhibit 99.1
Luminex Corporation Reports Fourth Quarter and Full-Year 2020 Results
AUSTIN, Texas (February 8, 2020) – Luminex Corporation (Nasdaq: LMNX) today announced results for its fourth quarter and full-year ended December 31, 2020.
All amounts in this release are in conformity with U.S. generally accepted accounting principles ("GAAP").
CURRENT FINANCIAL HIGHLIGHTS
•Record revenue for the fourth quarter of $111.4M, a 23% increase over Q4 2019, and record revenue for the year of $417.4M, up 25% vs. 2019, driven primarily by growth associated with the COVID-19 global pandemic
•Gross margins of 58% for the quarter and 59% for the full year, an improvement of 3 and 4 percentage points, respectively, vs. Q4 and full-year 2019
•Operating margin of $10.5M or 9% of revenue for the quarter and $42.4M or 10% of revenue for the year, an improvement of 250% and 450% vs. Q4 and full-year 2019
•Record net income for the year of $15.2M, or $0.32 per diluted share, up from net losses of $3.8M, or $0.09 per diluted share in 2019
CEO COMMENTARY
“I am very pleased with the overall performance of our diversified business during the past year. We have demonstrated an ability to adapt and deliver in unprecedented times, and our team continues to execute on our key role in addressing the demands of this global pandemic. We delivered record revenue growth, profitability, and cash flow during 2020 and positioned ourselves well for continued growth in 2021, and for the foreseeable future thereafter,” said Nachum “Homi” Shamir, Chairman, President and CEO of Luminex. “Our growth trajectory, expanding product portfolio, manufacturing capabilities and customer base, together with our financial strength, will enable us to consider a wide variety of exciting opportunities. I would like to thank all of our Luminex employees who have provided outstanding support during this pandemic that affects us all.”
ADDITIONAL HIGHLIGHTS OF THE QUARTER
•Molecular Diagnostics revenue for the quarter of $57.8M, up 49% vs. Q4 2019, and $227.8M for the year, up 67% vs. 2019
•Sold or contracted 449 sample-to-answer systems for the year, a significant number under reagent rental agreements, up nearly 120% vs. 2019 placements
•Licensed Technologies Group revenue of $40.0M, up 4% from Q4 2019, but down 2% from 2019, to $146.7M
•Flow Cytometry revenue of $12.0M, flat vs. Q4 2019, and $35.8M for the year, down 21% vs. 2019
| REVENUE SUMMARY | |||||||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||||||
| Three Months Ended | |||||||||||||||||||||||
| December 31, | Variance | ||||||||||||||||||||||
| 2020 | 2019 | ($) | (%) | ||||||||||||||||||||
| (unaudited) | |||||||||||||||||||||||
| System sales | $ | 23,758 | $ | 20,773 | $ | 2,985 | 14 | % | |||||||||||||||
| Consumable sales | 12,985 | 11,723 | 1,262 | 11 | % | ||||||||||||||||||
| Royalty revenue | 13,916 | 13,565 | 351 | 3 | % | ||||||||||||||||||
| Assay revenue | 51,300 | 36,374 | 14,926 | 41 | % | ||||||||||||||||||
| Service revenue | 6,331 | 5,651 | 680 | 12 | % | ||||||||||||||||||
| Other revenue | 3,103 | 2,415 | 688 | 28 | % | ||||||||||||||||||
| $ | 111,393 | $ | 90,501 | $ | 20,892 | 23 | % | ||||||||||||||||
| REVENUE SUMMARY | |||||||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||||||
| Twelve Months Ended | |||||||||||||||||||||||
| December 31, | Variance | ||||||||||||||||||||||
| 2020 | 2019 | ($) | (%) | ||||||||||||||||||||
| (unaudited) | |||||||||||||||||||||||
| System sales | $ | 70,764 | $ | 70,276 | $ | 488 | 1 | % | |||||||||||||||
| Consumable sales | 48,936 | 48,542 | 394 | 1 | % | ||||||||||||||||||
| Royalty revenue | 48,873 | 53,562 | (4,689) | (9) | % | ||||||||||||||||||
| Assay revenue | 211,902 | 132,028 | 79,874 | 60 | % | ||||||||||||||||||
| Service revenue | 23,341 | 22,413 | 928 | 4 | % | ||||||||||||||||||
| Other revenue | 13,580 | 7,817 | 5,763 | 74 | % | ||||||||||||||||||
| $ | 417,396 | $ | 334,638 | $ | 82,758 | 25 | % | ||||||||||||||||
REVENUE GUIDANCE
As of the date hereof, Luminex is providing revenue guidance as follows:
•Luminex reaffirms its 2021 revenue expectations of approximately $480 million, reflecting 15% growth over Luminex’s full year 2020, with such revenue growth driven primarily by significant expansion of ARIES® assay sales resulting from completion of the manufacturing line expansion, an expanded customer base, and new product launches.
CONFERENCE CALL
Management will host a conference call at 4:00 p.m. Central Time / 5:00 p.m. EDT, Monday, February 8, 2021 to discuss operating highlights and financial results for the fourth quarter and full-year 2020. The conference call will be webcast live and may be accessed at Luminex Corporation’s website at investor.luminexcorp.com. Analysts may participate on the conference call by dialing (877) 930-7053 (U.S.) or (253) 336-7290 (outside the U.S.). The access code is 4492199. The webcast will be archived for six months on our website using the 'replay' link.
ABOUT LUMINEX CORPORATION
At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. We accelerate reliable answers while simplifying complexity and deliver certainty with a seamless experience. To learn more about Luminex, please visit us at luminexcorp.com.
USE OF FORWARD-LOOKING STATEMENTS
Statements made in this release that express Luminex’s or management's intentions, plans, beliefs, expectations, or predictions of future events are forward-looking statements. Forward-looking statements in this release include statements regarding expected revenue and cost savings, projected 2021 performance, including revenue guidance, and expectations regarding Luminex’s product development, manufacturing line expansion and product growth and the continued impact of the COVID-19 pandemic on Luminex’s operations and financial results. The words “expect,” “anticipate,” “will,” “should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that Luminex’s actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex’s actual results or performance to differ materially include risks and uncertainties relating to, among others, negative effects from the worldwide COVID-19 pandemic (including but not limited to the general economic downturn related to such pandemic, travel restrictions related thereto, business closures that may affect our supply chain or our ability to install instruments, and delays in U.S. Food and Drug Administration (the “FDA”) clearances related to adjustments in the agency’s approval priorities in response to the pandemic), the warning letter (the “Warning Letter”) Luminex received from the FDA on June 26, 2020 relating to the operations of Luminex’s Austin, TX and Northbrook, IL facilities and Luminex’s VERIGENE Processor SP System, as previously disclosed in Luminex’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on June 29, 2020, including the outcome of Luminex’s efforts to remediate the FDA’s observations, the possible resolution of the issues identified in the Warning Letter and any further regulatory and enforcement actions that may initiated by the FDA with respect thereto, concentration of Luminex’s revenue in a limited number of direct customers and strategic partners, some of which may be experiencing decreased demand for their products utilizing or incorporating Luminex’s technology, budget or finance constraints in the current economic environment, or periodic variability in their purchasing patterns or practices as a result of internal resource planning challenges; market demand and acceptance of Luminex’s products and technologies, including ARIES®, MultiCode®, xMAP®, xMAP® INTELLIFLEX, VERIGENE®, VERIGENE® II, Guava®, Muse®, Amnis® and NxTAG® products; Luminex’s ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels; Luminex’s ability to obtain and enforce intellectual property protections on Luminex’s products and technologies; the impact on Luminex’s growth and future results of operations with respect to the loss of the LabCorp women’s health business; Luminex’s ability to successfully launch new products and complete new manufacturing lines in a timely manner; dependence on strategic partners for development, commercialization and distribution of products; risks and uncertainties associated with implementing Luminex’s acquisition strategy, including challenges in identifying acquisition targets, and obtaining financing on acceptable terms; Luminex’s ability to integrate acquired companies or selected assets into Luminex’s consolidated business operations, and its ability to fully realize the benefits of Luminex’s acquisitions; the timing of and process for regulatory approvals; competition and competitive technologies utilized by Luminex’s competitors; fluctuations in quarterly results due to a lengthy and unpredictable sales cycle; fluctuations in bulk purchases of consumables; fluctuations in product mix, and the seasonal nature of some of Luminex’s assay products; Luminex’s ability to comply with applicable laws, regulations, policies and procedures; the impact of the ongoing uncertainty in global finance markets and changes in governmental and governmental agency funding, including effects on the capital spending policies of Luminex’s partners and end users and their ability to finance purchases of Luminex’s products; changes in principal members of Luminex’s management staff; potential shortages, or increases in costs, of components or other disruptions to Luminex’s manufacturing operations; Luminex’s increasing dependency on information technology to improve the effectiveness of Luminex’s operations and to monitor financial accuracy and efficiency, including risks associated with potential attacks on or breaches of Luminex’s information technology systems and any resultant harm to Luminex’s ability to protect its intellectual property and manufacture, sell and support its products; the implementation, including any modification, of Luminex’s strategic operating plans; the uncertainty regarding the outcome or expense of any litigation brought against or initiated by Luminex; risks relating to Luminex’s foreign operations, including fluctuations in exchange rates, tariffs, customs and other barriers to importing/exporting materials and products in a cost effective and timely manner; difficulties in accounts receivable collections; Luminex’s ability to monitor and comply with foreign and international laws and treaties; Luminex’s ability to comply with changes in international taxation policies; budget or finance constraints of Luminex’s customers and partners in the current economic environment, or periodic variability in their purchasing patterns or practices as a result of material resource planning challenges; and Luminex’s reliance on third party distributors for distribution of specific Luminex-developed and manufactured assay products, as well as the risks discussed under the heading "Risk Factors" in Luminex’s Annual Reports on Forms 10-K and Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission.
The forward-looking statements, including the financial guidance and 2021 outlooks, contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
| Contacts: | ||||||||
| Harriss Currie | Carla Stanaford | Media Contact: | ||||||
| Senior Vice President, | Investor Relations | Michele Parisi | ||||||
| Chief Financial Officer | cstanaford@luminexcorp.com | Bioscribe | ||||||
| hcurrie@luminexcorp.com | 937-469-2120 | mparisi@bioscribe.com | ||||||
| 512-219-8020 | 925-864-5028 | |||||||
| LUMINEX CORPORATION | |||||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||||||
| (in thousands) | |||||||||||
| December 31, | December 31, | ||||||||||
| 2020 | 2019 | ||||||||||
| (unaudited) | |||||||||||
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 309,407 | $ | 59,173 | |||||||
| Accounts receivable, net | 66,963 | 55,815 | |||||||||
| Inventories, net | 123,134 | 77,084 | |||||||||
| Prepaids and other | 9,527 | 10,398 | |||||||||
| Total current assets | 509,031 | 202,470 | |||||||||
| Property and equipment, net | 64,146 | 65,515 | |||||||||
| Intangible assets, net | 78,796 | 90,336 | |||||||||
| Deferred income taxes | 21,077 | 27,702 | |||||||||
| Goodwill | 118,145 | 118,145 | |||||||||
| Right of use assets | 17,768 | 20,439 | |||||||||
| Other | 16,500 | 19,122 | |||||||||
| Total assets | $ | 825,463 | $ | 543,729 | |||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 21,049 | $ | 17,983 | |||||||
| Accrued liabilities | 56,365 | 31,872 | |||||||||
| Deferred revenue - current portion | 10,047 | 8,214 | |||||||||
| Total current liabilities | 87,461 | 58,069 | |||||||||
| Deferred revenue | 1,658 | 1,633 | |||||||||
| Lease liabilities | 13,366 | 17,182 | |||||||||
| Long-term debt | 203,136 | — | |||||||||
| Other long-term liabilities | 2,131 | 1,985 | |||||||||
| Total liabilities | 307,752 | 78,869 | |||||||||
| Stockholders' equity: | |||||||||||
| Common stock | 45 | 44 | |||||||||
| Additional paid-in capital | 434,021 | 380,304 | |||||||||
| Accumulated other comprehensive loss | (142) | (1,380) | |||||||||
| Retained earnings | 83,787 | 85,892 | |||||||||
| Total stockholders' equity | 517,711 | 464,860 | |||||||||
| Total liabilities and stockholders' equity | $ | 825,463 | $ | 543,729 | |||||||
| LUMINEX CORPORATION | |||||||||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||||||||||
| (in thousands, except per share amounts) | |||||||||||||||||||||||
| Three Months Ended | Twelve Months Ended | ||||||||||||||||||||||
| December 31, | December 31, | ||||||||||||||||||||||
| 2020 | 2019 | 2020 | 2019 | ||||||||||||||||||||
| (unaudited) | (unaudited) | ||||||||||||||||||||||
| Revenue | $ | 111,393 | $ | 90,501 | $ | 417,396 | $ | 334,638 | |||||||||||||||
| Cost of revenue | 46,949 | 40,636 | 169,544 | 151,899 | |||||||||||||||||||
| Gross profit | 64,444 | 49,865 | 247,852 | 182,739 | |||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Research and development | 13,796 | 12,933 | 53,651 | 56,228 | |||||||||||||||||||
| Selling, general and administrative | 37,229 | 31,098 | 140,216 | 127,183 | |||||||||||||||||||
| Amortization of acquired intangible assets | 2,919 | 2,851 | 11,542 | 11,407 | |||||||||||||||||||
| Total operating expenses | 53,944 | 46,882 | 205,409 | 194,818 | |||||||||||||||||||
| Income (loss) from operations | 10,500 | 2,983 | 42,443 | (12,079) | |||||||||||||||||||
| Interest and other expense, net | (5,023) | 3,196 | (11,912) | 3,100 | |||||||||||||||||||
| Loss from equity method investment | (241) | (523) | (1,591) | (523) | |||||||||||||||||||
| Income (loss) before income taxes | 5,236 | 5,656 | 28,940 | (9,502) | |||||||||||||||||||
| Income tax (expense) benefit | (4,997) | (2,273) | (13,770) | 5,664 | |||||||||||||||||||
| Net income (loss) | $ | 239 | $ | 3,383 | $ | 15,170 | $ | (3,838) | |||||||||||||||
| Net income (loss) attributable to common stockholders | |||||||||||||||||||||||
| Basic | $ | 236 | $ | 3,322 | $ | 14,873 | $ | (3,773) | |||||||||||||||
| Diluted | $ | 235 | $ | 3,322 | $ | 14,872 | $ | (3,775) | |||||||||||||||
| Net income (loss) per share attributable to common stockholders | |||||||||||||||||||||||
| Basic | $ | 0.01 | $ | 0.08 | $ | 0.33 | $ | (0.09) | |||||||||||||||
| Diluted | $ | 0.01 | $ | 0.07 | $ | 0.32 | $ | (0.09) | |||||||||||||||
| Weighted-average shares used in computing net income (loss) per share | |||||||||||||||||||||||
| Basic | 45,640 | 44,263 | 45,102 | 44,148 | |||||||||||||||||||
| Diluted | 45,985 | 44,503 | 45,820 | 44,148 | |||||||||||||||||||
| Dividends declared per share | $ | 0.10 | $ | 0.09 | $ | 0.37 | $ | 0.30 | |||||||||||||||
| LUMINEX CORPORATION | |||||||||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||||||||||||||||||
| (in thousands) | |||||||||||||||||||||||
| Three Months Ended | Twelve Months Ended | ||||||||||||||||||||||
| December 31, | December 31, | ||||||||||||||||||||||
| 2020 | 2019 | 2020 | 2019 | ||||||||||||||||||||
| (unaudited) | (unaudited) | ||||||||||||||||||||||
| Cash flows from operating activities: | |||||||||||||||||||||||
| Net income (loss) | $ | 239 | $ | 3,383 | $ | 15,170 | $ | (3,838) | |||||||||||||||
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | |||||||||||||||||||||||
| Depreciation and amortization | 7,712 | 7,358 | 30,483 | 28,529 | |||||||||||||||||||
| Amortization of debt issuance costs | 2,623 | — | 6,533 | — | |||||||||||||||||||
| Stock-based compensation | 4,070 | 3,554 | 14,851 | 13,198 | |||||||||||||||||||
| Deferred income tax (benefit) expense | 215 | 3,526 | 6,593 | (7,444) | |||||||||||||||||||
| (Gain) loss on sale or disposal of assets | 505 | 409 | 851 | 641 | |||||||||||||||||||
| Loss on equity method investment | 241 | (2,719) | 1,592 | (2,719) | |||||||||||||||||||
| Other | 1,216 | 203 | 2,087 | (329) | |||||||||||||||||||
| Changes in operating assets and liabilities: | |||||||||||||||||||||||
| Accounts receivable, net | (6,503) | (10,004) | (11,139) | (2,440) | |||||||||||||||||||
| Inventories, net | (13,313) | (956) | (45,973) | (13,559) | |||||||||||||||||||
| Other assets | 4,499 | 819 | 4,125 | 4,789 | |||||||||||||||||||
| Accounts payable | 3,505 | (1,170) | 3,184 | 3,370 | |||||||||||||||||||
| Accrued liabilities | 6,359 | 1,326 | 19,686 | (5,630) | |||||||||||||||||||
| Deferred revenue | (13) | (421) | 1,888 | (1,031) | |||||||||||||||||||
| Net cash provided by (used in) operating activities | 11,355 | 5,308 | 49,931 | 13,537 | |||||||||||||||||||
| Cash flows from investing activities: | |||||||||||||||||||||||
| Purchase of property and equipment | (6,296) | (3,133) | (17,910) | (16,249) | |||||||||||||||||||
| Proceeds from business acquisition consideration, net of cash acquired | — | — | — | 1,916 | |||||||||||||||||||
| Purchase of equity method investment | — | (6,980) | (6,980) | ||||||||||||||||||||
| Proceeds from cost method investment | — | 735 | — | 734 | |||||||||||||||||||
| Acquired technology rights | — | (40) | 22 | (40) | |||||||||||||||||||
| Net cash used in investing activities | (6,296) | (9,418) | (17,888) | (20,619) | |||||||||||||||||||
| Cash flows from financing activities: | |||||||||||||||||||||||
| Proceeds from issuance of convertible note, net of issuance costs | — | — | 252,247 | — | |||||||||||||||||||
| Purchase of convertible notes bond hedge | — | — | (54,626) | — | |||||||||||||||||||
| Proceeds from issuance of warrants | — | — | 19,968 | — | |||||||||||||||||||
| Proceeds from issuance of common stock | 640 | 1,269 | 20,435 | 3,750 | |||||||||||||||||||
| Shares surrendered for tax withholding | (8) | (6) | (2,373) | (2,095) | |||||||||||||||||||
| Dividends paid | (4,187) | (4,055) | (16,485) | (12,153) | |||||||||||||||||||
| Net cash provided by (used in) financing activities | (3,555) | (2,792) | 219,166 | (10,498) | |||||||||||||||||||
| Effect of foreign currency exchange rate on cash | (551) | 24 | (975) | 312 | |||||||||||||||||||
| Change in cash and cash equivalents | 953 | (6,878) | 250,234 | (17,268) | |||||||||||||||||||
| Cash and cash equivalents, beginning of period | 308,454 | 66,051 | 59,173 | 76,441 | |||||||||||||||||||
| Cash and cash equivalents, end of period | $ | 309,407 | $ | 59,173 | $ | 309,407 | $ | 59,173 | |||||||||||||||